We report a case of fatal intoxication with 2% viscous lidocaine. A 18 month old infant was admitted after malaise and cardiorespiratory arrest at home. He was resuscitated, then seizures appeared before arrival at the hospital. Treatment was symptomatic, including cardiorespiratory resuscitation and administration of anticonvulsants. Identification of lidocaine and its metabolite monoethylglycinexylidide (MEGX) MEGX was performed after organic extraction by High Performance Liquid Chromatography (HPLC) with Diode Array Detection (DAD); the serum concentrations, determined by Fluorescence Polarisation Immuno Assay (FPIA), were: 1.1 micrograms/ml for lidocaine and 0.94 microgram/ml for MEGX (H + 7) and 0.30 microgram/ml for the lidocaine (Day + 1). Neurotoxic manifestations appear at lower concentrations than cardiotoxic symptoms which are correlated with plasma levels of lidocaine. The toxic symptoms begin with headache, hallucinations, seizure, coma, respiratory arrest and circulatory collapse. The toxic symptoms can persist even after the decrease of lidocaine concentration under therapeutic levels. There is no antidote and acute lidocaine toxicity is managed with supportive therapy (diazepam for seizures, intubation, chronotropic agents). Considering the gravity of these poisonings which remain rare, the 2% viscous lidocaine prescription is forbidden for children under 6 years old.
Download full-text PDF |
Source |
---|
BMC Infect Dis
December 2024
Department of Infectious Diseases, the Third People's Hospital of Chengdu, Chengdu, Sichuan, 610031, China.
To enhance the current clinical understanding and improve the diagnosis and treatment of Actinotignum schaalii infections, we have presented here a report of the case of recurrent infections at a periumbilical scar, induced by Actinotignum schaalii and complicated by abscess formation in a 50-year-old woman with persistent festering at the site of a periumbilical scar after laparoscopy 9 years ago, with subsequent ruptures over the past 2 years. Physical examination revealed a radial fold scar with localized redness and slight swelling of the skin below the navel. Although no significant increase in the local skin temperature was noted, tenderness was present.
View Article and Find Full Text PDFJ Pharm Pract
February 2025
Department of Family Medicine, Louisiana State University Health Sciences Center Shreveport, Shreveport, LA, USA.
Methotrexate (MTX) is a common medication used to treat rheumatoid arthritis (RA). MTX inhibits rapid cell turnover throughout the body which can lead to significant side effects. Patients who present with oral lesions may have suffered severe acute toxicity from MTX.
View Article and Find Full Text PDFAAPS PharmSciTech
March 2024
Department of Pharmaceutical Sciences, School of Pharmacy, The University of Texas at El Paso, 500 West University Ave, El Paso, Texas, 79902, USA.
Recently, vast efforts towards sustainability have been made in the pharmaceutical industry. In conventional oil-in-water (O/W) cream formulations, various petroleum-based excipients, namely mineral oil and petrolatum, are commonly used. Natural or synthetic excipients, derived from vegetable sources, were explored as alternatives to petroleum-based excipients in prototype topical creams, with 1% (w/w) lidocaine.
View Article and Find Full Text PDFSaudi Med J
January 2024
From the Department of Anesthesiology, The First Affiliated Hospital of Soochow University, Soochow, China.
Objectives: To investigate the effects and safety of lidocaine viscous gargle on postoperative sore throat (POST) in patients receiving a laryngeal mask airway (LMA) in general anesthesia.
Methods: In this randomized controlled trial, 90 patients undergoing urological surgery were allocated into 2 treatment arms (n=45): lidocaine viscous gargle before LMA insertion (Group G) and topical application of lidocaine viscous on the LMA (Group T). Outcome data were collected before placement of LMA (T0), after insertion of LMA (T1), immediately (T2), one hour (T3), and 24 hours after removal of LMA (T4).
AAPS PharmSciTech
September 2023
Jihua Laboratory, Jihua Institute of Biomedical Engineering and Technology, Foshan, 528000, People's Republic of China.
By selecting L-arginine as the hydrogen bond acceptor (HBA) and 2-hydroxypropyl-β-cyclodextrin (2HPβCD) as the hydrogen bond donor (HBD), deep eutectic solvents (DESs) with various water content were prepared at the 4:1 mass ratio of L-arginine to 2HPβCD with 40 to 60% of water, and were studied for its application in transdermal drug delivery system (TDDS). The hydrogen bond networks and internal chemistry structures of the DESs were measured by attenuated total reflection Fourier transform infrared (ATR-FTIR) and H-nuclear magnetic resonance spectroscopy (H-NMR), which demonstrated the successful synthesis of DESs. The viscosity of DES was decreased from 10,324.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!